Nov 19 (Reuters) - Alkermes ( ALKS ) said on Wednesday
it has sweetened its offer to buy Avadel Pharmaceuticals ( AVDL )
, beating a rival bid from Denmark's Lundbeck and
valuing the sleep disorder drugmaker at up to $2.37 billion.